Effect of Sotagliflozin on Kidney Function and Cardio‐Kidney‐Metabolic Parameters Across Baseline eGFR Subgroups in Patients With Type 2 Diabetes and Stage 4 CKD
Diabetes, Obesity and Metabolism · 2026-12 · 28 (12) · 11966-11970
DOI: 10.1111/dom.71256 ↗Kurz gefasst
Leserbrief in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 24.08.2026. Verfasst von Vikas S Sridhar und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Nephrology, University of British Columbia, Vancouver, British Columbia, Canada. Die Arbeit nennt 7 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Lexicon Pharmaceutical Inc.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medicine, Division of Nephrology, University of British Columbia, Vancouver, British Columbia, Canada.
- Department of Medicine, Division of Nephrology, University Health Network, Toronto, Ontario, Canada.
- Lexicon Pharmaceuticals, Inc, The Woodlands, Texas, USA.
ORCID-Profile: Luxcia Kugathasan, David Z I Cherney
Förderung
- Lexicon Pharmaceutical Inc
Zitieren
APA
Sridhar, V. S., Kugathasan, L., Girard, M., Davies, M. J., & Cherney, D. Z. I. (2026). Effect of Sotagliflozin on Kidney Function and Cardio‐Kidney‐Metabolic Parameters Across Baseline eGFR Subgroups in Patients With Type 2 Diabetes and Stage 4 CKD. Diabetes, Obesity and Metabolism, 28(12), 11966-11970. https://doi.org/10.1111/dom.71256
Vancouver
Sridhar VS, Kugathasan L, Girard M, Davies MJ, Cherney DZI. Effect of Sotagliflozin on Kidney Function and Cardio‐Kidney‐Metabolic Parameters Across Baseline eGFR Subgroups in Patients With Type 2 Diabetes and Stage 4 CKD. Diabetes, Obesity and Metabolism. 2026;28(12):11966-11970. doi:10.1111/dom.71256
BibTeX
@article{Sridhar2026,
author = {Sridhar, Vikas S and Kugathasan, Luxcia and Girard, Manon and Davies, Michael J and Cherney, David Z I},
title = {Effect of Sotagliflozin on Kidney Function and Cardio‐Kidney‐Metabolic Parameters Across Baseline eGFR Subgroups in Patients With Type 2 Diabetes and Stage 4 CKD},
journal = {Diabetes, Obesity and Metabolism},
year = {2026},
volume = {28},
number = {12},
pages = {11966--11970},
doi = {10.1111/dom.71256}
}
EUVIMED